Nuformix (LSE:NFX) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Nuformix Days Payable?

Nuformix's average Accounts Payable for the six months ended in Mar. 2024 was £0.26 Mil. Nuformix's Cost of Goods Sold for the six months ended in Mar. 2024 was £0.00 Mil.

The historical rank and industry rank for Nuformix's Days Payable or its related term are showing as below:

LSE:NFX' s Days Payable Range Over the Past 10 Years
Min: 139.76 Med: 247.52 Max: 10128.75
Current: 10128.75

During the past 6 years, Nuformix's highest Days Payable was 10128.75. The lowest was 139.76. And the median was 247.52.

LSE:NFX's Days Payable is ranked better than
94.96% of 714 companies
in the Biotechnology industry
Industry Median: 127.14 vs LSE:NFX: 10128.75

Nuformix's Days Payable stayed the same from Sep. 2022 (0.00) to Mar. 2024 (0.00).

Nuformix Days Payable Historical Data

The historical data trend for Nuformix's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix Days Payable Chart

Nuformix Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Days Payable

Get a 7-Day Free Trial

226.34

139.76

247.52

666.27

10,128.75

Nuformix Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Mar24
Days Payable	Get a 7-Day Free Trial										12,045.00	-	-	-	-

Competitive Comparison of Nuformix's Days Payable

For the Biotechnology subindustry, Nuformix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuformix's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's Days Payable distribution charts can be found below:

* The bar in red indicates where Nuformix's Days Payable falls into.

Nuformix Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Nuformix's Days Payable for the fiscal year that ended in Mar. 2022 is calculated as

	Days Payable (A: Mar. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Mar. 2021 )	+	Accounts Payable (A: Mar. 2022 ))	/	count )	/	Cost of Goods Sold (A: Mar. 2022 )	*	Days in Period
=	( (0.099	+	0.012)	/	2 )	/	0.002	*	365
=	0.0555					/	0.002	*	365
=	10,128.75

Nuformix's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0.274	+	0.253)	/	2 )	/	0	*	365 / 2
=	0.2635					/	0	*	365 / 2
=	N/A

Nuformix Days Payable Related Terms

Thank you for viewing the detailed overview of Nuformix's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuformix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

1RT:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.nuformix.com

Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.